TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation ; volume:25 ; number:1 ; day:25 ; month:7 ; year:2024 ; pages:1-13 ; date:12.2024
BMC immunology ; 25, Heft 1 (25.7.2024), 1-13, 12.2024
- Creator
-
Ota, Yosuke
Inagaki, Ryosaku
Nagai, Yasuhiro
Hirose, Yuko
Murata, Masashi
Yamamoto, Setsuko
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12865-024-00643-x
- URN
-
urn:nbn:de:101:1-2410102122085.333032053063
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ota, Yosuke
- Inagaki, Ryosaku
- Nagai, Yasuhiro
- Hirose, Yuko
- Murata, Masashi
- Yamamoto, Setsuko
- SpringerLink (Online service)
Other Objects (12)
Deoxyguanosine is a TLR7 agonist
Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells
Migrationsverhalten von NK-Zellen nach Stimulation mit dem TLR7-Agonisten Resiquimod
A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune
Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction
Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod
An in situ depot for the sustained release of a TLR7/8 agonist in combination with a TGFβ inhibitor promotes anti-tumor immune responses
dSP
Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes
T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles
Deoxyguanosine is a TLR7 agonist
Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells
Migrationsverhalten von NK-Zellen nach Stimulation mit dem TLR7-Agonisten Resiquimod
A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune
Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction
Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod
An in situ depot for the sustained release of a TLR7/8 agonist in combination with a TGFβ inhibitor promotes anti-tumor immune responses
dSP
Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes
T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles
Deoxyguanosine is a TLR7 agonist
Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells
Migrationsverhalten von NK-Zellen nach Stimulation mit dem TLR7-Agonisten Resiquimod
A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune
Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction
Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod
An in situ depot for the sustained release of a TLR7/8 agonist in combination with a TGFβ inhibitor promotes anti-tumor immune responses
dSP
Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes